Perspective: Evaluating Regulator Risk for Comparator Drug Products

Evaluating risks and developing mitigation strategies have become common industry practices in drug development. Regulatory agencies have adopted risk-based approaches in quality management, pharmaceutical development and postmarket surveillance of medicinal products.1-4